ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chemotherapy Drugs for Neuroblastoma Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-0I15053
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Chemotherapy Drugs for Neuroblastoma Market Research Report 2023
BUY CHAPTERS

Global Chemotherapy Drugs for Neuroblastoma Market Research Report 2025

Code: QYRE-Auto-0I15053
Report
May 2025
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer Inc
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris

Chemotherapy Drugs for Neuroblastoma Market Size

The global market for Chemotherapy Drugs for Neuroblastoma was valued at US$ 133 million in the year 2024 and is projected to reach a revised size of US$ 182 million by 2031, growing at a CAGR of 4.6% during the forecast period.

Chemotherapy Drugs for Neuroblastoma Market

Chemotherapy Drugs for Neuroblastoma Market

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can"t all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
North American market for Chemotherapy Drugs for Neuroblastoma is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Chemotherapy Drugs for Neuroblastoma is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Chemotherapy Drugs for Neuroblastoma include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chemotherapy Drugs for Neuroblastoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Drugs for Neuroblastoma.
The Chemotherapy Drugs for Neuroblastoma market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chemotherapy Drugs for Neuroblastoma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chemotherapy Drugs for Neuroblastoma manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Chemotherapy Drugs for Neuroblastoma Market Report

Report Metric Details
Report Name Chemotherapy Drugs for Neuroblastoma Market
Accounted market size in year US$ 133 million
Forecasted market size in 2031 US$ 182 million
CAGR 4.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Cyclophosphamide
  • Cisplatin or Carboplatin
  • Vincristine
  • Doxorubicin (Adriamycin)
  • Etoposide
  • Other
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Chemotherapy Drugs for Neuroblastoma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Chemotherapy Drugs for Neuroblastoma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Chemotherapy Drugs for Neuroblastoma Market growing?

Ans: The Chemotherapy Drugs for Neuroblastoma Market witnessing a CAGR of 4.6% during the forecast period 2025-2031.

What is the Chemotherapy Drugs for Neuroblastoma Market size in 2031?

Ans: The Chemotherapy Drugs for Neuroblastoma Market size in 2031 will be US$ 182 million.

Who are the main players in the Chemotherapy Drugs for Neuroblastoma Market report?

Ans: The main players in the Chemotherapy Drugs for Neuroblastoma Market are Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi, Accord Healthcare, Viatris

What are the Application segmentation covered in the Chemotherapy Drugs for Neuroblastoma Market report?

Ans: The Applications covered in the Chemotherapy Drugs for Neuroblastoma Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Chemotherapy Drugs for Neuroblastoma Market report?

Ans: The Types covered in the Chemotherapy Drugs for Neuroblastoma Market report are Cyclophosphamide, Cisplatin or Carboplatin, Vincristine, Doxorubicin (Adriamycin), Etoposide, Other

Recommended Reports

Oncology Drugs

Pediatric Oncology

Hematologic Malignancies

1 Chemotherapy Drugs for Neuroblastoma Market Overview
1.1 Product Definition
1.2 Chemotherapy Drugs for Neuroblastoma by Type
1.2.1 Global Chemotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cyclophosphamide
1.2.3 Cisplatin or Carboplatin
1.2.4 Vincristine
1.2.5 Doxorubicin (Adriamycin)
1.2.6 Etoposide
1.2.7 Other
1.3 Chemotherapy Drugs for Neuroblastoma by Application
1.3.1 Global Chemotherapy Drugs for Neuroblastoma Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Chemotherapy Drugs for Neuroblastoma Market Size Estimates and Forecasts
1.4.1 Global Chemotherapy Drugs for Neuroblastoma Revenue 2020-2031
1.4.2 Global Chemotherapy Drugs for Neuroblastoma Sales 2020-2031
1.4.3 Global Chemotherapy Drugs for Neuroblastoma Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Chemotherapy Drugs for Neuroblastoma Market Competition by Manufacturers
2.1 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2020-2025)
2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Chemotherapy Drugs for Neuroblastoma, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Product Type & Application
2.7 Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Date of Enter into This Industry
2.8 Global Chemotherapy Drugs for Neuroblastoma Market Competitive Situation and Trends
2.8.1 Global Chemotherapy Drugs for Neuroblastoma Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Chemotherapy Drugs for Neuroblastoma Players Market Share by Revenue
2.8.3 Global Chemotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Chemotherapy Drugs for Neuroblastoma Market Scenario by Region
3.1 Global Chemotherapy Drugs for Neuroblastoma Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Region: 2020-2031
3.2.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Region: 2020-2025
3.2.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Region: 2026-2031
3.3 Global Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2020-2031
3.3.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2020-2025
3.3.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2026-2031
3.4 North America Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.4.1 North America Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2031)
3.4.3 North America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.5.1 Europe Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2031)
3.5.3 Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Region
3.6.1 Asia Pacific Chemotherapy Drugs for Neuroblastoma Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Chemotherapy Drugs for Neuroblastoma Sales by Region (2020-2031)
3.6.3 Asia Pacific Chemotherapy Drugs for Neuroblastoma Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.7.1 Latin America Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2031)
3.7.3 Latin America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Market Facts & Figures by Country
3.8.1 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2031)
3.8.3 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2031)
4.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2020-2025)
4.1.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Type (2026-2031)
4.1.3 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2031)
4.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2020-2031)
4.2.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2020-2025)
4.2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Type (2026-2031)
4.2.3 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2031)
4.3 Global Chemotherapy Drugs for Neuroblastoma Price by Type (2020-2031)
5 Segment by Application
5.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2031)
5.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales by Application (2020-2025)
5.1.2 Global Chemotherapy Drugs for Neuroblastoma Sales by Application (2026-2031)
5.1.3 Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2031)
5.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2020-2031)
5.2.1 Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2020-2025)
5.2.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Application (2026-2031)
5.2.3 Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2020-2031)
5.3 Global Chemotherapy Drugs for Neuroblastoma Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Baxter Healthcare
6.1.1 Baxter Healthcare Company Information
6.1.2 Baxter Healthcare Description and Business Overview
6.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.1.5 Baxter Healthcare Recent Developments/Updates
6.2 Ingenus Pharmaceuticals
6.2.1 Ingenus Pharmaceuticals Company Information
6.2.2 Ingenus Pharmaceuticals Description and Business Overview
6.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.3 ANI Pharmaceuticals
6.3.1 ANI Pharmaceuticals Company Information
6.3.2 ANI Pharmaceuticals Description and Business Overview
6.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.3.5 ANI Pharmaceuticals Recent Developments/Updates
6.4 Teva Pharmaceuticals
6.4.1 Teva Pharmaceuticals Company Information
6.4.2 Teva Pharmaceuticals Description and Business Overview
6.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.4.5 Teva Pharmaceuticals Recent Developments/Updates
6.5 Qilu Pharmaceutical
6.5.1 Qilu Pharmaceutical Company Information
6.5.2 Qilu Pharmaceutical Description and Business Overview
6.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.5.5 Qilu Pharmaceutical Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Company Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Hikma Pharmaceuticals
6.7.1 Hikma Pharmaceuticals Company Information
6.7.2 Hikma Pharmaceuticals Description and Business Overview
6.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.7.5 Hikma Pharmaceuticals Recent Developments/Updates
6.8 Fresenius Kabi
6.8.1 Fresenius Kabi Company Information
6.8.2 Fresenius Kabi Description and Business Overview
6.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.8.5 Fresenius Kabi Recent Developments/Updates
6.9 Accord Healthcare
6.9.1 Accord Healthcare Company Information
6.9.2 Accord Healthcare Description and Business Overview
6.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.9.5 Accord Healthcare Recent Developments/Updates
6.10 Viatris
6.10.1 Viatris Company Information
6.10.2 Viatris Description and Business Overview
6.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Product Portfolio
6.10.5 Viatris Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chemotherapy Drugs for Neuroblastoma Industry Chain Analysis
7.2 Chemotherapy Drugs for Neuroblastoma Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chemotherapy Drugs for Neuroblastoma Production Mode & Process Analysis
7.4 Chemotherapy Drugs for Neuroblastoma Sales and Marketing
7.4.1 Chemotherapy Drugs for Neuroblastoma Sales Channels
7.4.2 Chemotherapy Drugs for Neuroblastoma Distributors
7.5 Chemotherapy Drugs for Neuroblastoma Customer Analysis
8 Chemotherapy Drugs for Neuroblastoma Market Dynamics
8.1 Chemotherapy Drugs for Neuroblastoma Industry Trends
8.2 Chemotherapy Drugs for Neuroblastoma Market Drivers
8.3 Chemotherapy Drugs for Neuroblastoma Market Challenges
8.4 Chemotherapy Drugs for Neuroblastoma Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer Inc
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
List of Tables
 Table 1. Global Chemotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Chemotherapy Drugs for Neuroblastoma Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Chemotherapy Drugs for Neuroblastoma Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Chemotherapy Drugs for Neuroblastoma Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Chemotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Chemotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Chemotherapy Drugs for Neuroblastoma Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Chemotherapy Drugs for Neuroblastoma, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Product Type & Application
 Table 12. Global Key Manufacturers of Chemotherapy Drugs for Neuroblastoma, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Chemotherapy Drugs for Neuroblastoma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Drugs for Neuroblastoma as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Chemotherapy Drugs for Neuroblastoma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Chemotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K Units)
 Table 18. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2025)
 Table 19. Global Chemotherapy Drugs for Neuroblastoma Sales by Region (2026-2031) & (K Units)
 Table 20. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Region (2026-2031)
 Table 21. Global Chemotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2025)
 Table 23. Global Chemotherapy Drugs for Neuroblastoma Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2026-2031)
 Table 25. North America Chemotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
 Table 27. North America Chemotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
 Table 28. North America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Chemotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Chemotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Chemotherapy Drugs for Neuroblastoma Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Chemotherapy Drugs for Neuroblastoma Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Chemotherapy Drugs for Neuroblastoma Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Chemotherapy Drugs for Neuroblastoma Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Chemotherapy Drugs for Neuroblastoma Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Chemotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Chemotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Chemotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Chemotherapy Drugs for Neuroblastoma Sales (K Units) by Type (2020-2025)
 Table 51. Global Chemotherapy Drugs for Neuroblastoma Sales (K Units) by Type (2026-2031)
 Table 52. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2020-2025)
 Table 53. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Type (2026-2031)
 Table 54. Global Chemotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Chemotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2020-2025)
 Table 57. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Type (2026-2031)
 Table 58. Global Chemotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Chemotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Chemotherapy Drugs for Neuroblastoma Sales (K Units) by Application (2020-2025)
 Table 61. Global Chemotherapy Drugs for Neuroblastoma Sales (K Units) by Application (2026-2031)
 Table 62. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2020-2025)
 Table 63. Global Chemotherapy Drugs for Neuroblastoma Sales Market Share by Application (2026-2031)
 Table 64. Global Chemotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Chemotherapy Drugs for Neuroblastoma Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2020-2025)
 Table 67. Global Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Application (2026-2031)
 Table 68. Global Chemotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Chemotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2026-2031)
 Table 70. Baxter Healthcare Company Information
 Table 71. Baxter Healthcare Description and Business Overview
 Table 72. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product
 Table 74. Baxter Healthcare Recent Developments/Updates
 Table 75. Ingenus Pharmaceuticals Company Information
 Table 76. Ingenus Pharmaceuticals Description and Business Overview
 Table 77. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product
 Table 79. Ingenus Pharmaceuticals Recent Developments/Updates
 Table 80. ANI Pharmaceuticals Company Information
 Table 81. ANI Pharmaceuticals Description and Business Overview
 Table 82. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product
 Table 84. ANI Pharmaceuticals Recent Developments/Updates
 Table 85. Teva Pharmaceuticals Company Information
 Table 86. Teva Pharmaceuticals Description and Business Overview
 Table 87. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product
 Table 89. Teva Pharmaceuticals Recent Developments/Updates
 Table 90. Qilu Pharmaceutical Company Information
 Table 91. Qilu Pharmaceutical Description and Business Overview
 Table 92. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product
 Table 94. Qilu Pharmaceutical Recent Developments/Updates
 Table 95. Pfizer Company Information
 Table 96. Pfizer Description and Business Overview
 Table 97. Pfizer Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Pfizer Chemotherapy Drugs for Neuroblastoma Product
 Table 99. Pfizer Recent Developments/Updates
 Table 100. Hikma Pharmaceuticals Company Information
 Table 101. Hikma Pharmaceuticals Description and Business Overview
 Table 102. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product
 Table 104. Hikma Pharmaceuticals Recent Developments/Updates
 Table 105. Fresenius Kabi Company Information
 Table 106. Fresenius Kabi Description and Business Overview
 Table 107. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product
 Table 109. Fresenius Kabi Recent Developments/Updates
 Table 110. Accord Healthcare Company Information
 Table 111. Accord Healthcare Description and Business Overview
 Table 112. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product
 Table 114. Accord Healthcare Recent Developments/Updates
 Table 115. Viatris Company Information
 Table 116. Viatris Description and Business Overview
 Table 117. Viatris Chemotherapy Drugs for Neuroblastoma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Viatris Chemotherapy Drugs for Neuroblastoma Product
 Table 119. Viatris Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Chemotherapy Drugs for Neuroblastoma Distributors List
 Table 123. Chemotherapy Drugs for Neuroblastoma Customers List
 Table 124. Chemotherapy Drugs for Neuroblastoma Market Trends
 Table 125. Chemotherapy Drugs for Neuroblastoma Market Drivers
 Table 126. Chemotherapy Drugs for Neuroblastoma Market Challenges
 Table 127. Chemotherapy Drugs for Neuroblastoma Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Chemotherapy Drugs for Neuroblastoma
 Figure 2. Global Chemotherapy Drugs for Neuroblastoma Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Chemotherapy Drugs for Neuroblastoma Market Share by Type: 2024 & 2031
 Figure 4. Cyclophosphamide Product Picture
 Figure 5. Cisplatin or Carboplatin Product Picture
 Figure 6. Vincristine Product Picture
 Figure 7. Doxorubicin (Adriamycin) Product Picture
 Figure 8. Etoposide Product Picture
 Figure 9. Other Product Picture
 Figure 10. Global Chemotherapy Drugs for Neuroblastoma Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Chemotherapy Drugs for Neuroblastoma Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Clinic
 Figure 14. Other
 Figure 15. Global Chemotherapy Drugs for Neuroblastoma Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Chemotherapy Drugs for Neuroblastoma Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Chemotherapy Drugs for Neuroblastoma Sales (2020-2031) & (K Units)
 Figure 18. Global Chemotherapy Drugs for Neuroblastoma Average Price (US$/Unit) & (2020-2031)
 Figure 19. Chemotherapy Drugs for Neuroblastoma Report Years Considered
 Figure 20. Chemotherapy Drugs for Neuroblastoma Sales Share by Manufacturers in 2024
 Figure 21. Global Chemotherapy Drugs for Neuroblastoma Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Chemotherapy Drugs for Neuroblastoma Players: Market Share by Revenue in Chemotherapy Drugs for Neuroblastoma in 2024
 Figure 23. Chemotherapy Drugs for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Chemotherapy Drugs for Neuroblastoma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
 Figure 26. North America Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
 Figure 27. United States Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
 Figure 30. Europe Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Chemotherapy Drugs for Neuroblastoma Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Region (2020-2031)
 Figure 38. China Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. China Taiwan Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Southeast Asia Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Chemotherapy Drugs for Neuroblastoma Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Chemotherapy Drugs for Neuroblastoma Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Chemotherapy Drugs for Neuroblastoma by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Chemotherapy Drugs for Neuroblastoma by Type (2020-2031)
 Figure 57. Global Chemotherapy Drugs for Neuroblastoma Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Chemotherapy Drugs for Neuroblastoma by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Chemotherapy Drugs for Neuroblastoma by Application (2020-2031)
 Figure 60. Global Chemotherapy Drugs for Neuroblastoma Price (US$/Unit) by Application (2020-2031)
 Figure 61. Chemotherapy Drugs for Neuroblastoma Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Chemotherapy for Neuroblastoma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neuroblastoma Chemotherapy Drugs Market Research Report 2025
Global Neuroblastoma Treatment Drugs Market Research Report 2025
Global Neuroblastoma Drugs Market Research Report 2024
Immunotherapy Drugs for Neuroblastoma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cisplatin Chemotherapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Breast Cancer Treatment Drugs Market Insights Forecast to 2030
Global Neuroblastoma Treatment Market Insights Forecast to 2030
Immunotherapy for Neuroblastoma Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chemotherapy Drug Market Insights Forecast to 2030
Global Anticancer Drugs Market Research Report 2025
Global Glioma Treatment Market Research Report 2025
Global Vincristine Market Research Report 2024
Global Platinum based Cancer Drug Market Insights Forecast to 2030
Platinum based Anticancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Nephroblastoma Chemotherapy Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vinblastine Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Chemotherapy Drugs Market Research Report 2024
Global Chemotherapy Syringe Pump Market Insights Forecast to 2030
Global Oral Chemotherapy Drugs Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions